Financial Performance - The company achieved total revenue of ¥1,092,286,202.46, representing a year-on-year growth of 102.11% [2] - Operating profit reached ¥224,938,481.95, with a year-on-year increase of 18.16% [4] - Net profit attributable to ordinary shareholders was ¥190,963,229.96, reflecting a growth of 21.07% compared to the previous year [4] Business Development - Blood product and non-blood product businesses maintained stable growth [4] - The company has established a professional sales team of over 100 members, which has significantly boosted sales in the blood product sector [4] - Sales are primarily concentrated in East and Central China, with weaker performance in South China [4] Market Trends - The estimated national plasma collection for 2018 is 8,800 tons, with a growth of 10% [6] - The company currently operates 12 plasma collection stations, with potential to achieve over 400 tons of collection [6] - The price of albumin and immunoglobulin has decreased by 5-10% year-on-year, while the price of fibrinogen has remained stable [6] Regulatory and Certification Updates - The company has completed internal rectification for GMP certification and is awaiting inspection by relevant authorities [7] - Plasma allocation has received approval from Jiangxi and Guangdong drug regulatory authorities, pending national approval [7] Sales and Marketing Strategy - The sales expense ratio has remained stable compared to 2017, with no significant increase expected [5] - Academic promotion efforts are focused on foundational work rather than new indications for products [5]

Group 1: Company Overview and Operations - The company, Boya Biological, has a focus on blood plasma collection and product development, with a goal to maintain a double-digit growth in plasma collection over the next three years, aiming to exceed 600 tons by 2023 [4] - In 2020, despite a 9% decrease in plasma collection due to the pandemic, Boya Biological managed to achieve slight growth in collection volume through improved donor culture and service levels [4] - The company plans to establish at least 20 new plasma collection stations by the end of the 14th Five-Year Plan, targeting a collection volume of over 800 tons [4] Group 2: Financial Performance and Debt Management - Boya Biological's major shareholder, Gaotejia Group, is actively working to resolve its debt crisis, having repaid 794 million yuan (including principal and interest) to Citic Bank as of March 15, 2021 [3] - The company is also set to receive a repayment of 723 million yuan from Suzhou Delai by April 3, 2021, which is part of a commitment to settle debts owed to Boya Biological [3] - The net profit for Tianan Pharmaceutical is expected to remain no less than 40 million yuan annually, while Nanjing Xinbai is projected to maintain a net profit of at least 60 million yuan [4] Group 3: Product Development and Market Strategy - Boya Biological has received production approval for its new product, PCC, in December 2020, with plans to launch a new product each year for the next three years [4] - The company is enhancing its marketing strategies to improve brand image and market share, particularly in the non-blood product sector [4] - The company is also focusing on internationalization as a key part of its strategic planning, with exports dependent on domestic market supply and demand [6] Group 4: Challenges and Future Outlook - The company faces challenges due to the impact of the pandemic on plasma collection and the need for regulatory compliance in its operations [5] - Despite these challenges, Boya Biological remains optimistic about future growth and is committed to supporting the development of the company [3] - The company is actively addressing the potential impacts of changes in control due to Gaotejia Group's debt restructuring [5]

博雅生物投资者关系活动记录表 编号：20210430 证券代码：300294 证券简称：博雅生物 博雅生物制药集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------------|--------------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 □分析师会议 \n□媒体采访 √业绩说明会 \n□新闻发布会 □路演活动 \n□电话会议 | | | 参与单位名称及 人员姓名 | | 详见"博雅生物投资者关系"微信小程序。 | | 时 间 | 2021 年 04 月 30 日 | 15:00 — 17:00 | | 地 点 网络远程 | | | | | | 博雅生物制药集团股份有限公司出席人员： | | | 总经理梁小明 | | | 上市公司接待 人员姓名 | 董事会秘书兼财务总监涂 ...

博雅生物投资者关系活动记录表 编号：20210901 证券代码：300294 证券简称：博雅生物 博雅生物制药集团股份有限公司投资者关系活动记录表 | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------------|--------------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n√电话会议 | | | 参与单位名称及 人员姓名 | 电话会议接入的投资者（约 | 150 人） | | 时 间 | 2021 年 09 月 01 日 15:00 | — 16:00 | | 地 点 不适用 | | | | | 博雅生物制药集团股份有限公司出席人员： | | | 上市公司接待 | 总经理梁小明 | | | 人员姓名 | 董事会秘书兼财务总监涂言 ...

博雅生物投资者关系活动记录表 1 证券代码：300294 证券简称：博雅生物 博雅生物制药集团股份有限公司投资者关系活动记录表 编号：20210728 | --- | --- | --- | |-------------------------|--------------------------------------------|----------------------------------------------------------------------------------------------| | | □特定对象调研 □分析师会议 | | | 投资者关系 | □媒体采访 □业绩说明会 | | | 活动类别 | □新闻发布会 □路演活动 | | | | √电话会议 | | | 参与单位名称及 人员姓名 | 详见附件：人员名单 | 1 和人员名单 2 | | 时 间 | 2021 年 07 月 27 | 日 15:00—15:50 （海通证券郑琴组织） | | | 2021 年 07 月 28 | 日 15:00--15:40 （光大证券王明瑞组织） | | 地 点 | 不适用 | | ...

博雅生物投资者关系活动记录表 证券代码：300294 证券简称：博雅生物 博雅生物制药集团股份有限公司投资者关系活动记录表 编号：20211101 | --- | --- | --- | |-------------------------|---------------------------------------------------------------------------------------|----------------------------------------------------| | 投资者关系 \n活动类别 | □特定对象调研 □分析师会议 \n□媒体采访 □业绩说明会 \n□新闻发布会 □路演活动 \n√电话会议 | | | 参与单位名称及 人员姓名 | 电话会议接入的投资者，详见附件清单 | | | 时 间 2021 | 年 11 月 01 | 日 15:00—16:00 | | 地 点 不适用 | | | | | 博雅生物制药集团股份有限公司出席人员： | | | 上市公司接待 | 总经理 梁小明 | | | 人员姓名 | 董事会秘书 涂言实 | | | | 财 ...

Management Changes - The management team is actively coordinating with China Resources Pharmaceutical for strategic planning and governance adjustments [1] - The board of directors is being re-elected, with the number of directors increasing from 7 to 9, allowing China Resources to appoint 6 out of 9 directors [1] Financial Performance - The company has launched PCC products this year, which are expected to positively impact revenue and profit from ton plasma sales [3] - The product mix is balanced, with albumin, immunoglobulin, and factor products each accounting for approximately one-third of total sales [3] Research and Development - The company is focusing on blood product R&D, with plans to introduce 3-4 new products during the 14th Five-Year Plan period [4] - Key products in development include factor VIII, which is expected to be approved for production next year, and high-concentration immunoglobulin, anticipated to enter the market in 2024 [3][4] Capacity Expansion - Preparatory work for new capacity construction is nearly complete, with formal construction expected to start after the new board's review [3] - The company is actively expanding plasma stations, particularly after China Resources became the largest shareholder [3][4] Market Strategy - The company aims to enhance its focus on blood products, aligning with China Resources' strategic requirements [4] - The company plans to double its plasma volume and improve product marketing and academic promotion efforts during the 14th Five-Year Plan [4] Goodwill and Risk Management - The company's goodwill, primarily from acquisitions, totals 660 million yuan, with no signs of impairment currently [4] - The impact of centralized procurement on blood products is expected to be minimal due to overall industry supply and demand dynamics [4]

Group 1: Company Expansion and Development - The company currently owns 14 plasma stations, with the latest approval received in early December 2021 for the Yangcheng station in Shanxi [2] - The company is actively promoting the expansion of plasma stations, although the application and approval process face uncertainties due to various factors [2] - The construction plan for the smart factory is under internal discussion and will be submitted for board and shareholder approval once finalized, which is crucial for the company's future rapid development [2] Group 2: Product Development and Market Impact - The company received production approval for PCC at the end of last year, with a focus on terminal development and market promotion for this product in 2022, which is expected to positively impact revenue and profit as market promotion deepens [2] - The company is currently applying for production approval for coagulation factor VIII, which is anticipated to have a positive impact on revenue once approved [3] Group 3: Policy and Market Environment - The impact of the Guangdong Alliance procurement policy on the company's blood products is limited, as the pricing method favors the lowest bid among competitors, ensuring basic hospital entry quantities and reducing secondary development difficulties [3] - The company is actively working on the renewal of plasma stations and has plans for potential acquisitions, with a focus on improving financial conditions through product development and supply chain enhancements [3] Group 4: Operational Performance - The performance of Tianan Pharmaceutical and Xinbai Pharmaceutical has declined in the past two years due to changes in the pharmaceutical environment, but the management is striving to stabilize operations through product structure optimization and cost reduction measures [3]

Group 1: Company Strategy and Goals - The company aims to double its plasma collection and production during the 14th Five-Year Plan period, focusing on blood products as its core business [2] - The strategic initiatives include continuous development of new products, with a goal of obtaining approval for one new product each year [2] - Marketing efforts will enhance product recognition in the terminal market, while capacity assurance will involve accelerating the construction of the smart factory [2] Group 2: Plasma Collection Plans - The company plans to increase plasma collection through two main approaches: optimizing existing plasma stations and establishing new ones [2] - By the end of the 14th Five-Year Plan, the annual collection volume is expected to reach 1,000 tons, with existing stations projected to collect 650-700 tons [2] - New plasma stations are targeted to achieve a collection volume of 400-1,100 tons by the end of the 14th Five-Year Plan [2] Group 3: Impact of COVID-19 - The pandemic has caused varying degrees of disruption to plasma collection at certain stations, with a total shortfall of approximately 6 tons from planned collection during January to April [3] - Despite localized outbreaks, the overall control of the pandemic is deemed effective, and the company aims to catch up on its collection targets [3] Group 4: Current Status of Danxia Biology - Danxia Biology has restored operations at 8 plasma stations, with ongoing efforts to improve product development and sales [3] - The company is also considering debt restructuring to enhance its financial situation and plans to initiate mergers and acquisitions in compliance with regulatory requirements [3] Group 5: Strategic Cooperation with Gaotie Group - A strategic cooperation agreement has been signed with Gaotie Group to continue collaboration in the blood products sector, focusing on plasma station investment, quality control, and production process optimization [3] - This partnership aims to leverage mutual strengths to accelerate the development of Huaren Boya's blood product business [3]

华润博雅生物投资者关系活动记录表 证券代码：300294 证券简称：博雅生物 华润博雅生物制药集团股份有限公司投资者关系活动记录表 编号：20220622 | --- | --- | --- | --- | --- | |-----------------|---------------------------------------------|------------------------------------------------------------|---------|------------------| | | | | | | | | □特定对象调研 □分析师会议 | | | | | | □媒体采访 □业绩说明会 | | | | | 投资者关系活 | □新闻发布会 □路演活动 | | | | | 动类别 | □现场参观 | | | | | | | √电话会议（光大证券医药组王凯旋主持） | | | | 参与单位名称 | 见附件 | | | | | 及人员姓名 | | | | | | 时间 | 2022 年 06 月 22 日 | | | | | 地点 | 不适用 | | | | | 上市 ...